ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTGN

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of common stock of Vistagen Therapeutics, Inc. for the period between April 1, 2024, and December 16, 2025, due to alleged misleading statements regarding the company's drug fasedienol [1][5][6]. Group 1: Lawsuit Details - The lawsuit claims that Vistagen provided investors with overly positive information about the development and commercialization of fasedienol, an investigational drug for social anxiety disorder [5]. - Defendants allegedly made false and misleading statements while concealing material adverse facts about the Phase 3 PALISADE-3 trial, leading to artificially inflated stock prices [6]. Group 2: Investor Information - Investors who purchased Vistagen common stock during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][7]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].